SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY ARTICLE M impact

Evercore ISI cuts Ultragenyx Pharma PT to $16.00 from $34.00

Evercore ISI Group cut its price target for Ultragenyx Pharma to $16.00 per share from $34.00 and moved the rating to In-Line from Outperform, per Benzinga.

RARE

Ratings actions GMT) Ultragenyx Pharma Cut to In-Line From Outperform by Evercore ISI GroupRatings actions